NasdaqGS - Delayed Quote • USD
Replimune Group, Inc. (REPL)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:02 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 5 | 8 | 8 |
| Avg. Estimate | -0.79 | -0.8 | -3.27 | -3.03 |
| Low Estimate | -0.86 | -0.86 | -3.53 | -3.4 |
| High Estimate | -0.7 | -0.75 | -3.15 | -2.51 |
| Year Ago EPS | -0.74 | -0.75 | -2.99 | -3.27 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 5 | 9 | 9 |
| Avg. Estimate | -- | -- | -- | 4.81M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 43M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.67 | -0.84 | -0.86 | -0.93 |
| EPS Actual | -0.74 | -0.75 | -0.9 | -0.77 |
| Difference | -0.07 | 0.09 | -0.04 | 0.16 |
| Surprise % | -10.40% | 10.70% | -4.70% | 17.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.79 | -0.8 | -3.27 | -3.03 |
| 7 Days Ago | -0.79 | -0.8 | -3.27 | -3.03 |
| 30 Days Ago | -0.79 | -0.8 | -3.27 | -3.03 |
| 60 Days Ago | -0.79 | -0.8 | -3.27 | -3.03 |
| 90 Days Ago | -0.94 | -0.94 | -3.52 | -3.29 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | REPL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -6.80% | -- | -- | 5.40% |
| Next Qtr. | -6.70% | -- | -- | 10.90% |
| Current Year | -9.40% | -- | -- | 4.50% |
| Next Year | 7.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Barclays: Overweight to Overweight | 12/6/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
| Reiterates | Wedbush: Outperform to Outperform | 11/8/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/7/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/1/2023 |
| Maintains | JP Morgan: Overweight to Overweight | 6/15/2023 |
Related Tickers
YMAB Y-mAbs Therapeutics, Inc.
14.71
-0.88%
SRRK Scholar Rock Holding Corporation
14.53
+4.08%
STRO Sutro Biopharma, Inc.
3.4200
0.00%
STOK Stoke Therapeutics, Inc.
12.41
+6.16%
IDYA IDEAYA Biosciences, Inc.
39.94
+3.42%
IPSC Century Therapeutics, Inc.
2.8800
-8.57%
BCYC Bicycle Therapeutics plc
22.73
+0.93%
PASG Passage Bio, Inc.
1.3200
+8.20%
RGNX REGENXBIO Inc.
16.19
+0.81%
ITOS iTeos Therapeutics, Inc.
10.80
+1.89%